Fmr LLC Has $327,000 Stake in Precigen, Inc. (NASDAQ:PGEN)

Fmr LLC boosted its holdings in shares of Precigen, Inc. (NASDAQ:PGEN) by 26.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 345,204 shares of the biotechnology company’s stock after buying an additional 72,033 shares during the period. Fmr LLC owned about 0.14% of Precigen worth $327,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of PGEN. Iridian Asset Management LLC CT grew its position in Precigen by 82.5% in the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after acquiring an additional 1,706,815 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Precigen by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after purchasing an additional 127,467 shares in the last quarter. Renaissance Technologies LLC boosted its position in Precigen by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after buying an additional 130,500 shares in the last quarter. ClariVest Asset Management LLC grew its stake in Precigen by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock worth $778,000 after buying an additional 13,752 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Precigen by 4.8% during the second quarter. Bank of New York Mellon Corp now owns 421,788 shares of the biotechnology company’s stock worth $666,000 after buying an additional 19,301 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Precigen in a report on Friday, November 15th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.00.

Precigen Trading Up 5.1 %

Shares of NASDAQ PGEN opened at $0.76 on Friday. Precigen, Inc. has a 1-year low of $0.65 and a 1-year high of $1.93. The company has a 50-day moving average of $0.85 and a two-hundred day moving average of $1.15. The company has a market cap of $223.34 million, a PE ratio of -1.39 and a beta of 1.71.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.